Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 7 | 7 |
| List of Tables | 10 | 2 |
| List of Figures | 12 | 2 |
| Dermatology Therapeutics Market to 2018 - Introduction | 14 | 1 |
| Dermatology Therapeutics Market to 2018 - Market Overview | 15 | 5 |
| Revenue | 15 | 1 |
| Annual Cost of Treatment | 16 | 1 |
| Treatment Usage Pattern | 17 | 1 |
| Diseased Population | 18 | 1 |
| Treatment-Seeking Population | 18 | 1 |
| Diagnosed Population | 18 | 1 |
| Prescription Population | 18 | 1 |
| Recently Approved Product | 18 | 1 |
| Fabior (Tazarotene) | 18 | 1 |
| Overview | 18 | 1 |
| Mechanism of Action | 18 | 1 |
| Clinical Trial Details | 19 | 1 |
| Key Trends | 19 | 1 |
| Potential New Treatment for Skin Diseases | 19 | 1 |
| Innovative Medicines Initiative Launched in Europe to Address Antibiotic Resistance | 19 | 1 |
| Dermatology Therapeutics Market to 2018 - Geographical Landscape | 20 | 15 |
| Revenue by Country | 20 | 2 |
| The US | 22 | 1 |
| Revenue | 22 | 1 |
| Annual Cost of Treatment | 23 | 1 |
| Treatment Usage Pattern | 24 | 1 |
| Diseased Population | 25 | 1 |
| Treatment-Seeking Population | 25 | 1 |
| Diagnosed Population | 25 | 1 |
| Prescription Population | 25 | 1 |
| Top Five Countries in Europe | 25 | 1 |
| Revenue | 25 | 3 |
| Annual Cost of Treatment | 28 | 1 |
| Treatment Usage Pattern | 29 | 1 |
| Diseased Population | 30 | 1 |
| Treatment-Seeking Population | 30 | 1 |
| Diagnosed Population | 30 | 1 |
| Prescription Population | 30 | 1 |
| Japan | 31 | 1 |
| Revenue | 31 | 1 |
| Annual Cost of Treatment | 32 | 1 |
| Treatment Usage Pattern | 33 | 1 |
| Diseased Population | 34 | 1 |
| Treatment-Seeking Population | 34 | 1 |
| Diagnosed Population | 34 | 1 |
| Prescription Population | 34 | 1 |
| Dermatology Therapeutics Market to 2018 - Therapeutic Landscape | 35 | 61 |
| Global Alopecia Therapeutics Market | 35 | 1 |
| Introduction | 35 | 1 |
| Alopecia Areata | 35 | 1 |
| Androgenetic Alopecia | 35 | 1 |
| Revenue | 36 | 2 |
| Revenue by Country | 38 | 1 |
| Branded Versus Generics | 39 | 1 |
| Annual Cost of Treatment | 40 | 1 |
| Treatment Usage Pattern | 41 | 1 |
| Diseased Population | 42 | 1 |
| Treatment-Seeking Population | 42 | 1 |
| Diagnosed Population | 42 | 1 |
| Prescription Population | 42 | 1 |
| Treatment Algorithm | 42 | 1 |
| Drivers and Restraints | 43 | 1 |
| Drivers | 43 | 1 |
| Restraints | 44 | 1 |
| Global Herpes Therapeutics Market | 44 | 1 |
| Introduction | 44 | 1 |
| Herpes Simplex | 44 | 1 |
| Herpes Zoster | 45 | 2 |
| Revenue | 47 | 1 |
| Revenue by Country | 48 | 2 |
| Branded Versus Generics | 50 | 1 |
| Annual Cost of Treatment | 51 | 1 |
| Treatment Usage Pattern | 52 | 1 |
| Diseased Population | 53 | 1 |
| Treatment-Seeking Population | 53 | 1 |
| Diagnosed Population | 53 | 1 |
| Prescription Population | 53 | 1 |
| Treatment Algorithm | 54 | 1 |
| Drivers and Restraints | 55 | 1 |
| Drivers | 55 | 1 |
| Restraints | 55 | 1 |
| Global Psoriasis Therapeutics Market | 56 | 1 |
| Introduction | 56 | 1 |
| Revenue | 57 | 2 |
| Revenue by Country | 59 | 2 |
| Branded Versus Generics | 61 | 1 |
| Annual Cost of Treatment | 62 | 1 |
| Treatment Usage Pattern | 63 | 1 |
| Diseased Population | 64 | 1 |
| Treatment-Seeking Population | 64 | 1 |
| Diagnosed Population | 64 | 1 |
| Prescription Population | 65 | 1 |
| Treatment Algorithm | 65 | 1 |
| Drivers and Restraints | 66 | 1 |
| Drivers | 66 | 1 |
| Restraints | 67 | 1 |
| Global Acne Therapeutics Market | 67 | 1 |
| Introduction | 67 | 1 |
| Revenue | 68 | 2 |
| Revenue by Country | 70 | 1 |
| Branded Versus Generics | 71 | 1 |
| Annual Cost of Treatment | 72 | 1 |
| Treatment Usage Pattern | 73 | 1 |
| Diseased Population | 74 | 1 |
| Treatment-Seeking Population | 74 | 1 |
| Diagnosed Population | 74 | 1 |
| Prescription Population | 74 | 1 |
| Treatment Algorithm | 75 | 1 |
| Drivers and Restraints | 76 | 1 |
| Drivers | 76 | 1 |
| Restraints | 77 | 1 |
| Global Rosacea Disease Therapeutics Market | 77 | 1 |
| Introduction | 77 | 1 |
| Revenue | 78 | 1 |
| Revenue by Country | 79 | 1 |
| Branded Versus Generics | 80 | 1 |
| Annual Cost of Treatment | 81 | 1 |
| Treatment Usage Pattern | 82 | 1 |
| Diseased Population | 83 | 1 |
| Treatment-Seeking Population | 83 | 1 |
| Diagnosed Population | 83 | 1 |
| Prescription Population | 83 | 1 |
| Treatment Algorithm | 84 | 1 |
| Drivers and Restraints | 85 | 1 |
| Drivers | 85 | 1 |
| Restraints | 85 | 1 |
| Global Atopic Dermatitis Therapeutics Market | 86 | 1 |
| Introduction | 86 | 1 |
| Revenue | 86 | 2 |
| Revenue by Country | 88 | 1 |
| Branded Versus Generics | 89 | 1 |
| Annual Cost of Treatment | 90 | 1 |
| Treatment Usage Pattern | 91 | 1 |
| Diseased Population | 92 | 1 |
| Treatment-Seeking Population | 92 | 1 |
| Diagnosed Population | 92 | 1 |
| Prescription Population | 92 | 1 |
| Treatment Algorithm | 93 | 1 |
| Drivers and Restraints | 94 | 1 |
| Drivers | 94 | 1 |
| Restraints | 95 | 1 |
| Dermatological Therapeutics Market - Asia-Pacific Countries | 96 | 12 |
| India | 96 | 1 |
| Healthcare Overview | 96 | 1 |
| Regulatory Landscape | 96 | 1 |
| New Drug Pricing Policy | 96 | 2 |
| Market Overview | 98 | 1 |
| Key Trends | 99 | 1 |
| Free Medicines to Everyone from October | 99 | 1 |
| Compulsory License to Reduce Costs | 99 | 1 |
| Patient Protection and Affordable Care Act to Encourage Indian Generic Drug Manufacturers | 100 | 1 |
| Company Analysis | 100 | 1 |
| GlaxoSmithKline | 100 | 1 |
| Glenmark | 101 | 1 |
| Galderma | 102 | 1 |
| Biocon | 102 | 1 |
| Novartis | 102 | 1 |
| Ipca | 102 | 1 |
| Drivers and Restraints | 103 | 1 |
| China | 104 | 1 |
| Market Overview | 104 | 1 |
| Key Trends | 104 | 1 |
| Patented Law Amended for Cheaper Drugs | 104 | 1 |
| Pharmaceutical-Related Regulations Introduced in 2010 | 104 | 1 |
| Australia | 105 | 1 |
| Market Overview | 105 | 1 |
| Pricing and Reimbursement | 106 | 2 |
| Dermatological Therapeutics Market to 2018 - Pipeline Analysis | 108 | 21 |
| Introduction | 108 | 2 |
| Research and Development Pipeline - Alopecia | 110 | 1 |
| Research and Development Pipeline - Herpes | 111 | 1 |
| Research and Development Pipeline - Psoriasis | 112 | 1 |
| AIN457 | 112 | 1 |
| Anti-CD6 Monoclonal Antibody | 113 | 1 |
| CF101 | 113 | 1 |
| Tofacitinib | 114 | 1 |
| Research and Development Pipeline - Acne vulgaris | 115 | 1 |
| Research and Development Pipeline - Rosacea | 116 | 1 |
| Research and Development Pipeline - Atopic Dermatitis | 117 | 1 |
| Key R&D Trends | 117 | 1 |
| Promising Molecules - NDA Filed | 118 | 1 |
| LAS 41002 | 118 | 1 |
| Overview | 118 | 1 |
| Mechanism of Action | 118 | 1 |
| Clinical Trial Details | 118 | 1 |
| Low-Dose Duac | 119 | 1 |
| Overview | 119 | 1 |
| Mechanism of Action | 119 | 1 |
| Clinical Trial Details | 119 | 1 |
| Acnex | 120 | 1 |
| Overview | 120 | 1 |
| Mechanism of Action | 120 | 1 |
| Clinical Trial Details | 121 | 1 |
| Promising Molecules - Phase III | 121 | 1 |
| Zoster | 121 | 1 |
| Overview | 121 | 1 |
| Mechanism of Action | 121 | 1 |
| Clinical Trial Details | 121 | 1 |
| ARYS-01 | 121 | 1 |
| Overview | 121 | 1 |
| Mechanism of Action | 122 | 1 |
| Clinical Trial Details | 122 | 1 |
| V212 | 123 | 1 |
| Overview | 123 | 1 |
| Mechanism of Action | 123 | 1 |
| Clinical Trial Details | 123 | 1 |
| CC-10004 | 124 | 1 |
| Overview | 124 | 1 |
| Mechanism of Action | 124 | 1 |
| Clinical Trial Details | 124 | 1 |
| CD07805/47 | 125 | 1 |
| Overview | 125 | 1 |
| Mechanism of Action | 125 | 1 |
| Clinical Trial Details | 125 | 1 |
| Promising Molecules - Phase II | 125 | 1 |
| EPB-348 | 125 | 1 |
| Overview | 125 | 1 |
| Mechanism of Action | 125 | 1 |
| Clinical Trial Details | 126 | 1 |
| AMG 827 | 126 | 1 |
| Overview | 126 | 1 |
| Mechanism of Action | 126 | 1 |
| Clinical Trial Details | 126 | 1 |
| V-101 | 127 | 1 |
| Overview | 127 | 1 |
| Mechanism of Action | 127 | 1 |
| Clinical Trial Details | 127 | 1 |
| MK-3222 | 128 | 1 |
| Overview | 128 | 1 |
| Mechanism of Action | 128 | 1 |
| Clinical Trial Details | 128 | 1 |
| Dermatology Therapeutics Market to 2018 - Competitive Landscape | 129 | 21 |
| Market Share Analysis: Dermatological Disorders | 129 | 3 |
| Competitive Profiling | 132 | 1 |
| Johnson &Johnson | 132 | 1 |
| Company Overview | 132 | 1 |
| Product Portfolio | 132 | 2 |
| SWOT Analysis | 134 | 1 |
| Amgen | 134 | 1 |
| Company Overview | 134 | 1 |
| Product Portfolio | 134 | 1 |
| SWOT Analysis | 135 | 1 |
| Merck &Co. | 136 | 1 |
| Company Overview | 136 | 1 |
| Product Portfolio | 136 | 1 |
| SWOT Analysis | 137 | 1 |
| Abbott Laboratories | 137 | 1 |
| Company Overview | 137 | 1 |
| Product Portfolio | 138 | 1 |
| SWOT Analysis | 139 | 1 |